Status:
COMPLETED
Immune Monitoring on Sipuleucel-T
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this protocol is perform comprehensive immune monitoring studies in patients with castration-resistant prostate cancer receiving Sipuleucel-T in an effort to better understand the mecha...
Detailed Description
The primary objectives of this study are to: 1. Establish the phenotype and frequency of circulating immune cell compartments in patients undergoing treatment with Sipuleucel-T. 2. Determine the indu...
Eligibility Criteria
Inclusion
- Age \> 18 years of age
- Written informed consent obtained
- Patients with castration-resistant prostate cancer who are initiating Sipuleucel-T as standard therapy
- No prior systemic chemotherapy for metastatic prostate cancer
- Hemoglobin \> 9 mg/dl
Exclusion
- Patients unable to understand the research protocol and/or provide informed consent
Key Trial Info
Start Date :
June 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT02237170
Start Date
June 1 2012
End Date
December 1 2016
Last Update
January 4 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Comprehensive Cancer Center of Nevada
Las Vegas, Nevada, United States, 89169
2
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
3
Weill Cornell Medical College
New York, New York, United States, 10065